ASH CLL Spotlight | Conferences

High Response Rate With Venetoclax in Relapsed/Refractory CLL

December 07, 2016

Two-thirds of patients with chronic lymphocytic leukemia that progressed on B-cell receptor pathway inhibitors had objective responses to treatment with venetoclax (Venclexta), results of a small open-label trial showed.

An Overview of a Study Combining Nivolumab With Ibrutinib in CLL and Richter Transformation

December 06, 2016

Nitin Jain, MD, assistant professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses a phase II trial combining nivolumab (Opdivo) with ibrutinib (Imbruvica) for chronic lymphocytic leukemia (CLL) and richter transformation (RT) during the American Society of Hematology (ASH) Annual Meeting.

Induction of Ibrutinib Regimen Achieves 100% Response Rate in CLL

December 06, 2016

Combination induction therapy with ibrutinib (Imbruvica) and obinutuzumab (Gazyva) after bendamustine debulking induced a 100% response rate in patients with chronic lymphocytic leukemia (CLL), according to findings from the phase II CLL2-BIG trial.

Lenalidomide Maintenance Substantially Improved PFS in High-Risk Subgroup of CLL

December 05, 2016

Lenalidomide as maintenance following first-line immunochemotherapy substantially improves progression-free survival in the treatment of patients with high-risk chronic lymphocytic leukemia (CLL), according to interim analysis of the phase III CLLM1 study.

Ibrutinib Shows Impressive 5-Year Results in CLL/SLL

December 05, 2016

Findings from the longest follow-up to date evaluating up to 5 years of ibrutinib (Imbruvica) in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) show that the agent is safe and effective.